US OptionsDetailed Quotes
HRTX241220C5500
- 0.20
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
0.20Open0.20Pre Close0 Volume336 Open Interest5.50Strike Price0.00Turnover549.69%IV432.71%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.3529Delta0.2363Gamma5.35Leverage Ratio-0.0112Theta0.0001Rho1.89Eff Leverage0.0011Vega
Heron Therapeutics Stock Discussion
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time
- The VAN is expected to launch in Q4 2024
SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced tha...
1 min ago
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle ("Van")
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
No comment yet